Abstract Library

#3798 Intra-arterial PRRT – A prospective clinical study in NET patients with hepatic metastases

Introduction: Liver metastases of neuro-endocrine tumors have a significant impact on survival of patients treated with 177Lu-DOTATATE.

Conference:

Presenting Author:

Authors: Ebbers S, Barentsz M, de Vries-Huizing D, Versleijen M, Klompenhouwer L,

Keywords: PRRT, intra-arterial, lutetium, neuroendocrine tumor, peptide receptor radionuclide therapy, treatment response,

#3396 Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuro-endocrine tumor liver metastases

Introduction: In radioembolization, response is achieved through the irradiation and damaging of tumor DNA, while treatment toxicity is mainly related to healthy liver dose. Therefore, optimizing the dose in tumors while minimizing the healthy liver dose is deemed important. However, for hepatic metastases of neuroendocrine tumors, a dose-response relationship has not been established yet.

Conference:

Presenting Author: Ebbers S

Authors: Ebbers S, van Roekel C, Braat M, Barentsz M, Lam M,

Keywords: dose-response, neuroendocrine neoplasm, SIRT, 90y, radioembolization, liver metastasis,

#3107 Predicting response after [166Ho]-radioembolization in patients with neuroendocrine tumor liver metastases using neutrophil-to-lymphocyte and thrombocyte-to-lymphocyte ratios

Introduction: Response after treatment with [166Ho]-radioembolization is difficult to predict in patients with NET. Neutrophil-to-lymphocyte ratio (NLR) and thrombocyte-to-lymphocyte ratio (TLR) have been described as prognosticators for response.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ebbers S

Authors: Ebbers S, Brabander T, Tesselaar M, Hofland J, Barentsz M,

Keywords: PRRT, NET, neuroendocrine tumor, neuroendocrine neoplasm, lutetium-177-dotatate, radioembolization, holmium-166, objective response, NLR, TLR,

#3105 Hematotoxicity of Holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial PRRT

Introduction: In patients with neuroendocrine tumor liver metastases, additional tumor reduction can be achieved by sequential treatment with [166Ho]-radioembolization after peptide receptor radionuclide therapy (PRRT).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ebbers S

Authors: Ebbers S, Brabander T, Tesselaar M, Hofland J, Barentsz M,

Keywords: PRRT, NET, neuroendocrine tumor, neuroendocrine neoplasm, lutetium-177-dotatate, radioembolization, holmium-166, hematologic toxicity,